March 28, 2019, at 11 am PT/2 pm ET
23andMe’s Familial Hypercholesterolemia Report
Last month, 23andMe released the Familial Hypercholesterolemia Genetic Health Risk report* to eligible customers who have opted into receiving health reports. This report looks for 24 variants associated with familial hypercholesterolemia*.
Join our webinar for healthcare professionals on Thursday, March 28th, 11:00am-11:30am PT/2:00-2:30pm ET to learn about the science behind our new report, FDA requirements for genetic health risk reports and how genetic risk information is communicated to consumers. We will provide a walkthrough of the consumer experience and answer questions that are submitted during a live Q&A session.
View sample reports and package insert for Familial Hypercholesterolemia report.
This webinar is intended for healthcare professionals.
Jamaica Perry, PhD, is a Senior Product Scientist and manages the Clinical Health team at 23andMe. She coordinates feasibility, development, and implementation of health reports, and assists with FDA submissions. Jamaica holds a bachelor’s degree in biology from Northwestern University, as well as a Masters degree in Regulatory Science and a PhD in neuroscience from the University of Southern California.
*The 23andMe PGS test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. The Familial Hypercholesterolemia genetic health risk report is indicated for reporting of one variant in the APOB gene and 23 variants in the LDLR gene and describes if a person has variants associated with an increased risk of developing very high LDL cholesterol, which can lead to heart disease. The majority of the variants included in this report have been most studied in people of European and Lebanese descent, as well as in the Old Order Amish.